

EXPORT LICENSE

NRC FORM 250



United States of America
 Nuclear Regulatory Commission
 Washington, D.C. 20555

NRC LICENSE NO.: XMAT448/03

Page 1 of 16

NRC DOCKET NO.: 11006349

LICENSE EXPIRES: December 6, 2021

Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

<p align="center">LICENSEE</p> <p>Cambridge Isotope Laboratories, Inc. 50 Fontage Road Andover, MA 01810</p> <p>Attn: Rebecca Dabkowski</p>	<p align="center">ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</p> <p align="center">See following page(s)</p>
<p align="center">INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</p> <p align="center">See following page(s)</p>	<p align="center">OTHER U.S. PARTY(IES) TO EXPORT</p> <p align="center">See following page(s)</p>

APPLICANT'S REFERENCE: XMAT448

ULTIMATE DESTINATIONS: India and France

<p align="center">QUANTITY(IES)</p>	<p align="center">DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)</p> <p>This license is amended to: 1) include additional Ultimate Foreign Consignee(s); 2) revising the names of Ultimate Foreign Consignee(s); 3) revise the date of expiration from May 31, 2025 to December 6, 2021; and 4) update the addresses to Other U.S. Parties to Export.</p> <p>The license is authorized to export a cumulative total 10,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds. The cumulative total starts from the issuance of the original license XMAT448.</p>
--	---

Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.

This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC.

THIS LICENSE IS INVALID UNLESS SIGNED BELOW BY AUTHORIZED NRC REPRESENTATIVE

SIGNATURE: David Skeen
Digitally signed by David Skeen
 Date: 2021.10.06 09:26:43 -04'00'

NAME AND TITLE: David L. Skeen, Deputy Director
 Office of International Programs

DATE OF ISSUANCE: October 6, 2021

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
2. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
3. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
4. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
5. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
6. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
7. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
8. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

9. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

10. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

11. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

12. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

13. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

14. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

15. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

16. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

17. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

18. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

19. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

20. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

21. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

22. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

23. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

24. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

25. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

26. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

27. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

28. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

29. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

30. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

31. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

32. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

33. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

34. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

35. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

36. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

37. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

38. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

39. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

40. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

41. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

42. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

43. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

44. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

45. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

46. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

47. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

48. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

49. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

50. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

51. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

52. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

53. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

54. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

55. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

56. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

57. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

58. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

59. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

60. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

61. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

62. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

63. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

64. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

65. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

66. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

67. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

68. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

69. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

70. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

71. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

72. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

73. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

74. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

75. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

76. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

77. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

78. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

79. [REDACTED]
Iceland
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

80. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

81. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

82. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

83. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

84. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

85. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

86. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

87. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

88. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

89. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

90. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

91. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

92. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

93. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

94. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

95. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

96. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

97. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

98. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

99. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

100. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

101. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

102. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

103. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

104. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

105. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

106. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

107. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

108. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1. [REDACTED]
India
(for distribution to ultimate consignees)

2. [REDACTED]
India
(for distribution to ultimate consignees)

3. [REDACTED]
India
(for distribution to ultimate consignees)

4. [REDACTED]
India
(for distribution to ultimate consignees)

INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

5. [REDACTED]

France

(for distribution to ultimate consignees)

6. [REDACTED]

India

(for distribution to ultimate consignees)

7. [REDACTED]

India

(for distribution to ultimate consignees)

8. [REDACTED]

India

(for distribution to ultimate consignees)

9. [REDACTED]

India

(for distribution to ultimate consignees)

10. [REDACTED]

India

(for distribution to ultimate consignees)

OTHER U.S. PARTY(IES) TO EXPORT:

1. Cambridge Isotope Laboratories, Inc.
6 Highwood Drive
Tewksbury, MA 01876
(supplier)

2. Cambridge Isotope Laboratories, Inc.
50 Frontage Road
Andover, MA 01810
(supplier/distributors)

3. Cambridge Isotope Separations
1689 Burnett Drive
Xenia, OH 45385
(supplier)